Ainos, Inc. (AIMD) Stock Price & Analysis
Ainos, Inc. (AIMD) fell 7.28% to USD 1.4 as of July 25, 2026 at 05:10 UTC, according to Nexqual real-time market data.
AIMD last closed at USD 1.51; the session ranged USD 1.38–1.57 on volume of 39,298 shares. Market capitalization is $10.31M, with a 52-week range of USD 1.26–4.5 (NCM). Source: Nexqual, July 25, 2026 at 05:10 UTC.
Key Statistics (as of July 25, 2026 at 05:10 UTC)
| Price | USD 1.4 |
|---|---|
| Change | ▼ 7.28% (down) |
| Previous Close | USD 1.51 |
| Open | USD 1.57 |
| Day Range | USD 1.38 – 1.57 |
| 52-Week Range | USD 1.26 – 4.5 |
| Volume | 39,298 shares |
| Market Cap | $10.31M |
| Exchange | NCM |
Technical Analysis (AIMD)
Nexqual's technical model rates AIMD "SELL" based on 3 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:10 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.38 (oversold) |
| vs SMA50 | Below (USD 1.9) |
| MACD | -0.11 (negative) |
Analyst Ratings (AIMD)
Wall Street analysts rate AIMD "None", per Nexqual as of July 25, 2026 at 05:10 UTC.
| Consensus Rating | None |
|---|
Earnings (AIMD)
Source: Nexqual, July 25, 2026 at 05:10 UTC.
Financials & Fundamentals (AIMD)
| Total Revenue | $18,111 |
|---|---|
| Revenue Growth (YoY) | -99.80% |
| Gross Margin | +79.15% |
| Operating Margin | -1418414.30% |
| Profit Margin | +0.00% |
| ROE | -148.24% |
| Debt / Equity | 242.68 |
| Current Ratio | 0.56 |
| Total Cash | $2.84M |
| Total Debt | $13.81M |
| Free Cash Flow | $616,062 |
Source: Nexqual, July 25, 2026 at 05:10 UTC.
Financial Health Score (AIMD)
Nexqual rates Ainos, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:10 UTC.
| Growth | Critical — Revenue -100% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Critical — $3M cash vs $14M debt |
| Cash Flow | Strong — FCF $616K, 460% margin |
| Efficiency | Critical — ROE -148%, ROA -33.8% |
Ownership (AIMD)
| Insider Ownership | +61.80% |
|---|---|
| Institutional Ownership | +1.56% |
| Shares Outstanding | 7.36M |
| Float | 2.38M |
| Short % of Float | +0.39% |
Source: Nexqual, July 25, 2026 at 05:10 UTC.
Leadership (AIMD)
Ainos, Inc. is led by Chun-Hsien Tsai (age 55), CEO, President & Chairman of the Board, per Nexqual as of July 25, 2026 at 05:10 UTC.
| CEO, President & Chairman of the Board | Chun-Hsien Tsai (age 55) |
|---|---|
| Chief Financial Officer | Hsin-Liang Lee (age 54) |
| Director of Corporate Developoment | Chih-Heng Lu (age 45) |
Major Backers & Investors (AIMD)
Notable institutional backers of Ainos, Inc. include Fidelity, Mariner, LLC, Keystone Financial Group, according to Nexqual as of July 25, 2026 at 05:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.59% |
| Mariner, LLC | 0.36% |
| Keystone Financial Group | 0.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.62% |
| Vanguard Group | 0.39% |
Source: Nexqual, July 25, 2026 at 05:10 UTC.
From Ainos, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Ltd. and its Taiwan subsidiary, Taiwan Inabata Sangyo Co., Topco Scientific Co., Ltd., Trusval Technology Co., Ltd., Solomon Technology Corporation, Kenmec Mechanical Engineering Co., Ltd., and Topmed International Biotech Co., Ltd.   Intellectual Property   We seek to protect our technology and competitive position through a combination of patents, trade secrets, proprietary know-how, and other intellectual property rights.
- Our approach emphasizes expanding the role of scent as a machine-readable data modality alongside vision and sound, while maintaining flexibility to address diverse operational requirements.   Separately, we continue to develop VELDONA®, our low-dose oral interferon platform, targeting selected rare, autoimmune, and infectious disease indications.
- We also believe that maintaining operations in Taiwan in the near term enables us to access technical and scientific talent while managing operating costs, supporting the development of high-quality and cost-effective products.   Outsourced Manufacturing.
- We rely on an outsourced manufacturing model, which we believe allows us to manage capital efficiently and maintain operational flexibility.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. | USD 0.12 | ▼ 1.69% |
| BBLG | Bone Biologics Corp | USD 1.07 | ▼ 2.73% |
| ACON | Aclarion, Inc. | USD 2.42 | ▼ 5.1% |
| SPRC | SciSparc Ltd. | USD 5.33 | ▲ 10.12% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.55 | ▼ 7.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:10 UTC. This page is informational and not investment advice.